
November 13, 2023
RegMed Investors (RMi) Closing Bell: the curse of trial results
November 13, 2023
RegMed Investors’ (RMi) pre-open: after a dud of a week, any if some relief?
November 10, 2023
RegMed Investors (RMi) Closing Bell: the cell and gene therapy sector suffers from…
November 10, 2023
RegMed Investors’ (RMi) pre-open: which way as market breadth remains a challenge?
November 9, 2023
RegMed Investors (RMi) Closing Bell: sector fizzles following a Wednesday sputter
November 9, 2023
RegMed Investors’ (RMi) pre-open: sentiment loops in and fades out
November 8, 2023
RegMed Investors (RMi) Closing Bell: cell and gene therapy sector is punished for LPS (loss-per-share) in earnings season
November 8, 2023
RegMed Investors’ (RMi) pre-open: momentum or resistance?
November 7, 2023
RegMed Investors (RMi) Closing Bell: tailwinds pop the sector
November 7, 2023
RegMed Investors’ (RMi) pre-open: negative reaction to positive actions redefines contraction
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors